Newronika Secures €13.6 Million Series B Funding to Boost Adaptive DBS Platform Development
In a significant development for neurological therapies, Newronika, a leading innovator in advanced deep brain stimulation (DBS), has announced the successful completion of its Series B funding round, raising €13.6 million. Led by a new investor, Fondazione ENEA Tech e Biomedical, this round also saw contributions from existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F.
The infusion of capital will be pivotal for Newronika as it ramps up clinical validation and commercialization efforts for its unique adaptive DBS system. This innovative technology is specifically designed to provide tailored therapies that not only improve symptom relief for patients with Parkinson's disease but also minimize side effects. This strategic capital will facilitate advancements in product development, recruitment of top-tier talent, and the establishment of strategic partnerships that reinforce Newronika’s standing at the crossroads of medical device engineering and neuroscience.
The momentum behind Newronika's initiatives is further bolstered by a recent grant from the Michael J. Fox Foundation and the approval of an Investigational Device Exemption (IDE) by the FDA. These milestones showcase the company's commitment to leading a paradigm shift in the field of neuromodulation. The adaptive DBS technology epitomizes the future of personalized brain stimulation, and Newronika is wholeheartedly dedicated to steering this evolution.
Dr. Lorenzo Rossi, co-founder and CEO of Newronika, expressed enthusiasm about the investment round, saying, "We are excited about the strong backing from both existing and new investors. This Series B financing endorses our mission to transform how deep brain stimulation is delivered. Our aim is to seamlessly integrate real-time neural data and machine learning into our DBS systems to create truly personalized therapies that exceed the current market capabilities."
Maria Cristina Porta, CEO of ENEA Tech e Biomedical, shared her vision for the partnership: "Together with Newronika and their adaptive DBS platform, we see extraordinary opportunities to revolutionize movement disorder treatments globally. Their innovative approach, capable of real-time personalized neuromodulation, aligns perfectly with our vision of supporting groundbreaking medical technologies. We are thrilled to partner with Newronika to deliver next-generation DBS solutions to patients in need. Investing in such technologies is about taking care of people's health while also generating value and fostering innovation within our country's ecosystem."
Davide Turco, the CEO of Indaco, remarked on the ongoing support for Newronika's initiatives, stating, "Indaco is proud to continue backing Newronika through our Indaco Venture I - Lombardia Parallel Fund as it navigates through the upcoming clinical and commercial phases. We are confident that Newronika's adaptive DBS system will enhance the quality of life for countless patients suffering from Parkinson's disease."
Claudio Giuliano, President of Newronika, underscored the strategic vision behind the successful Series B funding, noting, "This financing round reinforces Newronika's strategic vision and commitment to pushing the boundaries of DBS technology for the benefit of patients.”
About the Investors
ENEA Tech e Biomedical is an Italian foundation focused on supporting high-impact projects in biotechnology, medical devices, and life sciences, aiming for transformative solutions to global healthcare challenges.
Indaco Venture Partners SGR is one of Italy's largest venture capital firms, investing equally through its Indaco Ventures I Fund and the Lombardia Parallel Fund to promote cutting-edge innovations in healthcare and technology.
Innogest SGR specializes in venture capital for medical technology and digital health, leveraging its extensive experience to support innovative startups in the health sector. Wille Finance, based in Switzerland, focuses on impact investing across healthcare and transformative technology sectors. Additionally, TNBT Capital, based in Paris, invests in pioneering technologies in neuromodulation and neurotechnology while F3F is dedicated to investing in innovative medical technology companies revitalizing patient care.
About Newronika
Newronika is transforming deep brain stimulation (DBS) through its adaptive platform that optimizes therapy using real-time patient data. Based in Milan, Italy, the company is committed to advancing neuromodulation beyond conventional limits. With ongoing research collaborations, CE marking for its technology, and now an FDA exemption for experimental device testing, Newronika is at the forefront of next-generation therapeutic innovations for neurological disorders.
For more information, visit www.newronika.com and follow them on LinkedIn.
The infusion of capital will be pivotal for Newronika as it ramps up clinical validation and commercialization efforts for its unique adaptive DBS system. This innovative technology is specifically designed to provide tailored therapies that not only improve symptom relief for patients with Parkinson's disease but also minimize side effects. This strategic capital will facilitate advancements in product development, recruitment of top-tier talent, and the establishment of strategic partnerships that reinforce Newronika’s standing at the crossroads of medical device engineering and neuroscience.
The momentum behind Newronika's initiatives is further bolstered by a recent grant from the Michael J. Fox Foundation and the approval of an Investigational Device Exemption (IDE) by the FDA. These milestones showcase the company's commitment to leading a paradigm shift in the field of neuromodulation. The adaptive DBS technology epitomizes the future of personalized brain stimulation, and Newronika is wholeheartedly dedicated to steering this evolution.
Dr. Lorenzo Rossi, co-founder and CEO of Newronika, expressed enthusiasm about the investment round, saying, "We are excited about the strong backing from both existing and new investors. This Series B financing endorses our mission to transform how deep brain stimulation is delivered. Our aim is to seamlessly integrate real-time neural data and machine learning into our DBS systems to create truly personalized therapies that exceed the current market capabilities."
Maria Cristina Porta, CEO of ENEA Tech e Biomedical, shared her vision for the partnership: "Together with Newronika and their adaptive DBS platform, we see extraordinary opportunities to revolutionize movement disorder treatments globally. Their innovative approach, capable of real-time personalized neuromodulation, aligns perfectly with our vision of supporting groundbreaking medical technologies. We are thrilled to partner with Newronika to deliver next-generation DBS solutions to patients in need. Investing in such technologies is about taking care of people's health while also generating value and fostering innovation within our country's ecosystem."
Davide Turco, the CEO of Indaco, remarked on the ongoing support for Newronika's initiatives, stating, "Indaco is proud to continue backing Newronika through our Indaco Venture I - Lombardia Parallel Fund as it navigates through the upcoming clinical and commercial phases. We are confident that Newronika's adaptive DBS system will enhance the quality of life for countless patients suffering from Parkinson's disease."
Claudio Giuliano, President of Newronika, underscored the strategic vision behind the successful Series B funding, noting, "This financing round reinforces Newronika's strategic vision and commitment to pushing the boundaries of DBS technology for the benefit of patients.”
About the Investors
ENEA Tech e Biomedical is an Italian foundation focused on supporting high-impact projects in biotechnology, medical devices, and life sciences, aiming for transformative solutions to global healthcare challenges.
Indaco Venture Partners SGR is one of Italy's largest venture capital firms, investing equally through its Indaco Ventures I Fund and the Lombardia Parallel Fund to promote cutting-edge innovations in healthcare and technology.
Innogest SGR specializes in venture capital for medical technology and digital health, leveraging its extensive experience to support innovative startups in the health sector. Wille Finance, based in Switzerland, focuses on impact investing across healthcare and transformative technology sectors. Additionally, TNBT Capital, based in Paris, invests in pioneering technologies in neuromodulation and neurotechnology while F3F is dedicated to investing in innovative medical technology companies revitalizing patient care.
About Newronika
Newronika is transforming deep brain stimulation (DBS) through its adaptive platform that optimizes therapy using real-time patient data. Based in Milan, Italy, the company is committed to advancing neuromodulation beyond conventional limits. With ongoing research collaborations, CE marking for its technology, and now an FDA exemption for experimental device testing, Newronika is at the forefront of next-generation therapeutic innovations for neurological disorders.
For more information, visit www.newronika.com and follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.